Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 5/20 | 0.39 |
| ▸ | CECR2 | Q9BXF3 | 5/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.36 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597653 | 0.81 | TSHR (1.00) | TSHRALDH1A1GSK3AGSK3BPOLB | |
| SCHEMBL20393489 | 0.80 | TSHR (0.63) | TSHRALDH1A1GSK3AGSK3BATAD2 | |
| SCHEMBL2485668 | 0.76 | TSHR (0.63) | TSHRALDH1A1GSK3AGSK3BATAD2 | |
| SCHEMBL7454709 | 0.76 | TSHR (0.63) | TSHRALDH1A1GSK3AGSK3BATAD2 | |
| SCHEMBL16223202 | 0.76 | TSHR (0.58) | TSHRALDH1A1GSK3AGSK3BLMNA | |
| SCHEMBL12133543 | 0.73 | POLB (0.37) | TSHRALDH1A1POLBLMNA | |
| SCHEMBL5091798 | 0.73 | TSHR (0.44) | TSHRALDH1A1POLBLMNAMEN1 | |
| SCHEMBL181570 | 0.73 | — | — | |
| SCHEMBL29116577 | 0.72 | TSHR (0.53) | TSHRALDH1A1GSK3AGSK3BATAD2 | |
| SCHEMBL6976927 | 0.72 | MAPT (0.44) | TSHRALDH1A1POLBLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163536-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA SAS (FR) | 2021-06-03 | — | — | US | disclosed |
| US-10960046-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | RHYTHM PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190111105-A1 | Use of Melanocortins to Treat Insulin Sensitivity | IPSEN PHARMA S.A.S. (FR) | 2019-04-18 | — | — | US | disclosed |
| US-20180118784-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2018-05-03 | — | — | US | disclosed |
| US-9845339-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9827286-B2 | Use of melanocortins to treat insulin sensitivity | IPSEN PHARMA S.A.S. (FR) | 2017-11-28 | — | — | US | disclosed |
| US-9758549-B2 | Melanocortin receptor ligands modified with hydantoin | IPSEN PHARMA S.A.S. (FR) | 2017-09-12 | — | — | US | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| WO-2007015588-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | TSHR 496/4885ALDH1A1 915/4885GSK3A 4834/4885 |
| US-10960046-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | MC4R, MC5R, MC3R | TSHR 461/4885ALDH1A1 4504/4885GSK3A 643/4885 |
| US-20180118784-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | TSHR 341/4885ALDH1A1 2832/4885GSK3A 4564/4885 |
| US-20190111105-A1 | Use of Melanocortins to Treat Insulin Sensitivity | MC4R, MC1R, MC3R | TSHR 53/4885ALDH1A1 4304/4885GSK3A 2817/4885 |
| US-20210163536-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | TSHR 341/4885ALDH1A1 2832/4885GSK3A 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.